Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Brian Finck
Washington University, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Cirius Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
It was determined that Dr. Finck's personal financial relationship with Cirius Therapeutics, related to the above referenced research, creates a financial conflict of interest due to the following reasons:
• Cirius Therapeutics owns the Intellectual Property being evaluated in the research.
• Research could directly benefit the entity.
• His role as described below could directly affect the research.
While it was determined Dr. Finck has a financial conflict of interest, there are mitigating factors that help address the situation.
1. The research is early phase and basic.
2. The evaluation of the IP is not the primary aim of the research.
3. Additionally, a plan has been developed to mitigate the financial conflict of interest.
TARGETING THE MITOCHONDRIAL PYRUVATE CARRIER TO TREAT NONALCOHOLIC STEATOHEPATITIS
We have developed new drugs that we believe will be useful for treating nonalcoholic steatohepatitis (NASH), which is a common disease in the U.S. caused by having too much fat in the liver. The goal of this project is to test this idea in mice and to determine the mechanisms by how these drugs work. Successful completion of these studies could pave the way to clinical development of a pharmaceutical therapy for treatment of NASH.
Filed on January 10, 2018.
Tell us what you know about Brian Finck's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.